“The corporate, by way of its wholly-owned subsidiary Shilpa Biologicals Pvt Ltd (SBPL), has entered right into a three-year definitive settlement with Dr Reddy’s Laboratories for production-supply of the Sputnik V vaccine from its built-in biologics R&D cum manufacturing heart at Dharwad, Karnataka,” Shilpa Medicare mentioned in a regulatory submitting.
The focused manufacturing of the twin vector Sputnik V for the primary 12 months is 50 million doses (50 million of part 1 and 50 million of part 2), from the date of begin of economic manufacturing, the corporate added.
Shilpa Medicare mentioned Dr Reddy’s will facilitate the switch of the sputnik know-how to SBPL.
Below the settlement, SBPL can be liable for the manufacturing of the vaccine, whereas Dr Reddy’s is liable for distribution/advertising and marketing of the vaccine in its advertising and marketing territories.
Shilpa Medicare mentioned the businesses are additionally exploring the choice to fabricate Sputnik Light, a single dose model of the vaccine within the close to future.
Reddy’s Laboratories on Friday soft-launched imported Covid-19 vaccine Sputnik V, with Deepak Sapra, a senior govt of the drug-maker, taking the primary shot.
The imported Sputnik V vaccine is priced at Rs 948, with 5 p.c GST per dose (retail worth of Rs 995.40).
The primary consignment of imported doses of the Sputnik V vaccine from Russian Direct Investment Fund (RDIF) landed in India on Could 1 and acquired regulatory clearance from the Central Drugs Laboratory.